Norges Bank Satsuma Pharmaceuticals, Inc. Transaction History

Norges Bank

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.0 - $1.11 $0 - $19,647	-17,700 Closed	0 $0
Q2 2022 Aug 14, 2023	BUY	$2.59 - $4.3 $45,843 - $76,110	17,700 New	17,700 $73,000
Q1 2022 May 12, 2023	BUY	$3.78 - $5.32 $66,906 - $94,164	17,700 New	17,700 $67,000
Q1 2022 May 09, 2022	SELL	$3.78 - $5.32 $126,630 - $178,220	-33,500 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$4.15 - $6.24 $139,025 - $209,040	33,500 New	33,500 $151,000
Q3 2021 Nov 14, 2022	BUY	$4.54 - $7.17 $152,090 - $240,195	33,500 New	33,500 $156,000
Q3 2021 Nov 05, 2021	SELL	$4.54 - $7.17 $152,090 - $240,195	-33,500 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$4.8 - $7.25 $160,800 - $242,875	33,500 New	33,500 $236,000
Q2 2021 Aug 10, 2021	SELL	$4.8 - $7.25 $836,265 - $1.26 Million	-174,222 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$4.57 - $7.18 $796,194 - $1.25 Million	174,222 New	174,222 $1.03 Million
Q4 2019 Feb 12, 2020	SELL	$9.32 - $19.68 $139,800 - $295,200	-15,000 Closed	0 $0
Q3 2019 Nov 13, 2020	BUY	$14.98 - $16.9 $224,700 - $253,499	15,000 New	15,000 $225,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.